Cefozopran

This classification denotes a cephalosporin antibiotic with the molecular formula C19H17N9O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1LG87K28LW, chemically known as imidazo(1,2-b)pyridazinium, 1-((7-(((5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, (6r-(6alpha,7beta(z)))- but generally known as cefozopran, which bears US NIH Compound Identifier 9571080. European Medicines Agency schedules Cefozopran in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07410MIG. The term CEFOZOPRAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules cefozopran in its Anatomical Therapeutic Chemical (ATC) Classification. CEFOZOPRAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefozopran under HS 29419000 and SITC 54139. As of Q4 2014, CEFOZOPRAN remains the US FDA Preferred Term for this commodity. Cefozopran bears US NLM identifiers UMLS ID C0246584 and NCI Concept Code C76172. SMILES: S1C2N(C(=O)C2NC(=O)/C(=N\OC)C2NC(SN2)N)C(=C(C1)CN1C2[N](NCCC2)CC1)C(=O)O.